Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.49
+0.01 (2.54%)
Market open: Aug 12, 2026, 9:54 AM EDT
0.48
-0.00 (-0.27%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
| Name | Position |
|---|---|
| Dr. Kartik Krishnan M.D., Ph.D. | Chief Medical Officer |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder & Executive Chairman |
| Dr. Tiago Reis Marques M.D., Ph.D. | CEO & Director |
| Mr. Daniel H. Schneiderman | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-07 | DEF 14A | ea0300656-def14a_pasithea.htm |
| 2026-08-07 | ARS | ea030065603-ars_pasithea.pdf |
| 2026-07-29 | PRE 14A | ea0298583-pre14a_pasithea.htm |
| 2026-05-15 | 10-Q | ea0289157-10q_pasithea.htm |
| 2026-05-04 | 8-K | ea0288864-8k_pasithea.htm |
| 2026-03-30 | 10-K | ea0275535-10k_pasithea.htm |
| 2026-02-20 | 8-K | ea0277843-8k_pasithea.htm |
| 2026-01-30 | S-8 | ea0274493-s8_pasithea.htm |
| 2026-01-28 | 8-K | ea0274244-8k_pasithea.htm |
| 2026-01-26 | POS AM | ea027402501-posam_pasithea.htm |